BioCentury | Jul 29, 2013
Company News

Avac Pharma Ltd., ChronTech deal

...ChronTech said newco Avac completed its acquisition of all of ChronTech's assets related to development programs...
...HCV. ChronTech could not be reached for details (see BioCentury, May 13 & May 27). Avac...
BioCentury | May 27, 2013
Company News

ChronTech infectious, drug delivery news

...company's assets related to development programs for DNA vaccines against HBV and HCV to newco Avac...
...company said a group of shareholders offered to acquire the assets through the formation of Avac...
...Marlborough, Mass.), as well as entire ownership of ChronTech's Ivin needle technology. ChronTech will grant Avac...
BioCentury | May 13, 2013
Company News

ChronTech infectious, drug delivery news

...for DNA vaccines against HBV and HCV for $1 million. The shareholders have formed newco Avac...
...Marlborough, Mass.), as well as entire ownership of ChronTech's Ivin needle technology. ChronTech will grant Avac...
...all relevant IP to develop and commercialize the vaccines in combination with the Ivin device. Avac...
BioCentury | Apr 14, 2008
Company News

SemBioSys, Avac Ltd. deal

...2006 deal to develop SemBioSys' safflower-produced insulin program, SemBioSys received a $350,000 milestone payment from Avac...
...under a 2006 deal for advancing the development of its Botaneco Specialty Ingredients Inc. subsidiary. Avac...
...that invests in Alberta companies, is eligible for royalties. SemBioSys Genetics Inc. (TSE:SBS), Calgary, Alberta Avac...
BioCentury | Mar 31, 2008
Finance

Ebb & Flow

...include Consensus Business Group, Caisse de depot et placement du Quebec, FIER Partners, BDC Capital, AVAC...
BioCentury | Jan 3, 2005
Company News

SemBioSys, Avac Ltd. deal

...SBS received $229,000 from Avac for reaching a third milestone in a deal to develop the...
...oilbodies engineered to have Protein A on their surface. SemBioSys Genetics Inc. (TSE:SBS), Calgary, Alberta Avac...
BioCentury | Sep 15, 2003
Clinical News

AVAC: Phase II

...Research and Development Corp. (ASX:GEN), Auckland, New Zealand SR Pharma plc (LSE:SPA), London, U.K. Product: AVAC...
BioCentury | Sep 10, 2003
Clinical News

Genesis, SR Pharma start Phase II eczema trial

...Research (ASE:GEN) and SR Pharma (LSE:SPA) started a placebo-controlled New Zealand Phase II trial of AVAC...
...score in atopic dermatitis (SASSAD) and safety. Data are expected at the end of 2004. AVAC...
BioCentury | Jun 30, 2003
Clinical News

SRP299: Phase I

...and Development Corp. (ASX:GEN), Auckland, New Zealand SR Pharma plc (LSE:SPA), London, U.K. Product: SRP299 (AVAC...
BioCentury | Mar 10, 2003
Clinical News

AVAC: Phase I

...In a New Zealand Phase I trial in 12 patients, 3 intradermal injections of AVAC at...
...Research and Development Corp. (NZSE/ASX:GEN), Auckland, New Zealand SR Pharma plc (LSE:SPA), London, U.K. Product: AVAC...
Items per page:
1 - 10 of 12
BioCentury | Jul 29, 2013
Company News

Avac Pharma Ltd., ChronTech deal

...ChronTech said newco Avac completed its acquisition of all of ChronTech's assets related to development programs...
...HCV. ChronTech could not be reached for details (see BioCentury, May 13 & May 27). Avac...
BioCentury | May 27, 2013
Company News

ChronTech infectious, drug delivery news

...company's assets related to development programs for DNA vaccines against HBV and HCV to newco Avac...
...company said a group of shareholders offered to acquire the assets through the formation of Avac...
...Marlborough, Mass.), as well as entire ownership of ChronTech's Ivin needle technology. ChronTech will grant Avac...
BioCentury | May 13, 2013
Company News

ChronTech infectious, drug delivery news

...for DNA vaccines against HBV and HCV for $1 million. The shareholders have formed newco Avac...
...Marlborough, Mass.), as well as entire ownership of ChronTech's Ivin needle technology. ChronTech will grant Avac...
...all relevant IP to develop and commercialize the vaccines in combination with the Ivin device. Avac...
BioCentury | Apr 14, 2008
Company News

SemBioSys, Avac Ltd. deal

...2006 deal to develop SemBioSys' safflower-produced insulin program, SemBioSys received a $350,000 milestone payment from Avac...
...under a 2006 deal for advancing the development of its Botaneco Specialty Ingredients Inc. subsidiary. Avac...
...that invests in Alberta companies, is eligible for royalties. SemBioSys Genetics Inc. (TSE:SBS), Calgary, Alberta Avac...
BioCentury | Mar 31, 2008
Finance

Ebb & Flow

...include Consensus Business Group, Caisse de depot et placement du Quebec, FIER Partners, BDC Capital, AVAC...
BioCentury | Jan 3, 2005
Company News

SemBioSys, Avac Ltd. deal

...SBS received $229,000 from Avac for reaching a third milestone in a deal to develop the...
...oilbodies engineered to have Protein A on their surface. SemBioSys Genetics Inc. (TSE:SBS), Calgary, Alberta Avac...
BioCentury | Sep 15, 2003
Clinical News

AVAC: Phase II

...Research and Development Corp. (ASX:GEN), Auckland, New Zealand SR Pharma plc (LSE:SPA), London, U.K. Product: AVAC...
BioCentury | Sep 10, 2003
Clinical News

Genesis, SR Pharma start Phase II eczema trial

...Research (ASE:GEN) and SR Pharma (LSE:SPA) started a placebo-controlled New Zealand Phase II trial of AVAC...
...score in atopic dermatitis (SASSAD) and safety. Data are expected at the end of 2004. AVAC...
BioCentury | Jun 30, 2003
Clinical News

SRP299: Phase I

...and Development Corp. (ASX:GEN), Auckland, New Zealand SR Pharma plc (LSE:SPA), London, U.K. Product: SRP299 (AVAC...
BioCentury | Mar 10, 2003
Clinical News

AVAC: Phase I

...In a New Zealand Phase I trial in 12 patients, 3 intradermal injections of AVAC at...
...Research and Development Corp. (NZSE/ASX:GEN), Auckland, New Zealand SR Pharma plc (LSE:SPA), London, U.K. Product: AVAC...
Items per page:
1 - 10 of 12